Accra, Ghana – July 28, 2026

Intravenous Infusions PLC Returns to Profitability and Enters a New Phase of Strong Growth

Intravenous Infusions PLC reported a return to profitability for the six-month period ended 30 June 2026. During the period, the Company successfully raised primary capital and initiated key operating strategies that resulted in a reset of production operations, a stronger revenue mix, and tighter control over operating expenses.

For 1H 2026, the Company reported revenue of GHS4.28 million. While the revenue represented a 39% year-on-year decline, the decrease was driven by a deliberate focus on the Company's higher-margin products and the exit from price-sensitive tenders and distribution lines that were eroding value and consuming working capital without generating adequate returns. Despite the lower revenue, gross profit improved by 44% year-on-year to GHS3.11 million, compared with GHS2.17 million in the corresponding period in 2025.

Operating and other expenses declined by 40% year-on-year following the implementation of cost-restructuring, efficiency initiatives, and tighter controls on overhead expenses. The combined improvement in gross profit and operating efficiency resulted in profit before finance costs and tax increasing approximately 29-times to GHS285,507, compared with GHS9,699 in 1H 2025. The Company also moved from a pre-tax loss to a pre-tax profit of GHS 236,824, and delivered a GHS202,282 year-on-year improvement in net profit when compared with results in 1H 2025.

IIPLC also took decisive steps in 1H 2026 to strengthen its capital base by successfully raising capital through a convertible loan, which improved stated capital by 41%. This marked a fundamental turning point for the business and established a strong platform from which to restore profitable long-term growth.

During 2H 2026, the Company will continue to execute against three strategic pillars: Portfolio Optimization, Cost and Operational Efficiency, and Commercial Momentum. The Board and management recognize that significant execution work remains. However, the return to profitability, substantial improvement in gross profit and strengthening of the Company's capital base represent a strong beginning to the Company's turnaround.

The Board and Management of Intravenous Infusions PLC remain focused on scaling profitable revenue, improving cash generation and delivering sustainable long-term value for shareholders.

For further information,
Please contact: Intravenous Infusions Investor Relations
Intravenous Infusions PLC

INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

Intravenous Infusions PLC

Unaudited Financial Statements
for the six months period ended
30 June 2026

INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF COMPREHENSIVE INCOME

	30 JUNE 2026 UNAUDITED GHS	30 JUNE 2025 UNAUDITED GHS	% CHANGE YOY
Revenue	4,283,423	7,073,903	-39%
Cost of operations	1,168,972	4,904,182	76%
Gross profit	**3,114,451**	**2,169,721**	**44%**
Other income	-	2,436,966	-
Operating and other expenses	2,554,687	4,290,379	40%
Profit before finance and tax	**285,507**	**9,699**	**2844%**
Finance cost	48,684	36,437	34%
Profit before tax	**236,824**	-26,738	-
Income tax expense	61,279	-	-
Profit for the period	**175,544**	**-26,738**	-
Earnings per share	0.0005	-0.0001	-

INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF FINANCIAL POSITION

	30 JUNE 2026 UNAUDITED GHS	30 JUNE 2025 UNAUDITED GHS	% CHANGE YOY
Assets			
Non-current assets			
Property, plant and equipment	25,601,115	24,273,120	5%
Investment	9,720	9,720	
Current assets			
Inventory	5,086,174	5,036,842	1%
Trade and other receivables	6,601,559	11,555,966	-43%
Current tax	728,403	-	
Cash	338,947	1,057,582	-68%
Total current assets	**12,755,083**	**17,650,390**	-28%
Total assets	**38,365,918**	**41,923,511**	-8%
Liabilities and equity			
Equity			
Stated capital	16,426,451	11,626,451	41%
Retained earnings	-2,258,063	2,154,574	-
Capital surplus	2,103,120	2,103,120	-
Total Equity	**16,271,508**	**15,884,145**	2%
Non-current Liabilities			
Deferred tax liability	-	551,263	-
Lease obligation	34,722	34,279	-1%
Medium term loan	-	4,318,612	-
Total non-current Liability	**34,722**	**4,904,151**	99%
Current liabilities			
Borrowings	9,299,868	3,944,965	-136%
Trade and other payables	12,759,819	17,190,250	26%
Current tax	-	-	
Employee benefit obligation	-	-	
Total current liabilities	**16,704,784**	**21,135,215**	4%
Total liabilities	**22,094,409**	**26,039,366**	15%
Total liabilities and equity	**38,365,918**	**41,923,511**	-8%

UNAUDITED STATEMENT OF CHANGES IN EQUITY

	Stated Capital	Deposit for Shares	Income Surplus	Capital Surplus	Total
Balance at 1st Jan 2026	11,626,451		(2,450,482)	2,103,120	11,279,089
issue of shares(net)					
Profit/(loss) for the period					
Dividend paid					
Additional Capital	4,800,000				4,800,000
Transfer from profit and loss			192,419		192,419
At 30th June 2026	**16,426,451**		**(2,258,063)**	**2,103,120**	**16,271,508**

INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF CASH FLOWS

	30 JUNE 2026 UNAUDITED GHS	30 JUNE 2025 UNAUDITED GHS
Operating activities		
Profit before tax	**236,824**	**-26,738**
Adjustments for non-cash income and expenses:		
Net employee obligation	-	-
Depreciation of property, plant and equipment	274,256	306,609
Cash flow included in operating activities	**559,764**	**279,871**
Changes in operating assets and liabilities		
Decrease/increase in trade and other receivables	1,396,563	1,135,588
Increase/decrease in trade payables	-5,282,750	-2,907,475
Increase/decrease in inventory	-555,128	-1,943,520
Cash flow from operating activities	**-3,881,551**	**451,503**
Tax paid	-	-
Dividend paid	-	-
Net cash from operating activities	**-3,881,551**	**451,504**
Cash flow from investing activities		
Purchases of equipment	-	-5,350
Net cash used in investing activities	**-**	**-5,350**
Cash flow from financing activities		
Increase in borrowings	4,199,612	-875,238
Net cash used in financing activities	**4,199,612**	**-875,238**
Net (increase/decrease) in cash and cash equivalents	318,061	-428,129
cash and cash equivalents at beginning of year	20,887	1,485,711
Cash and cash equivalents as 30 June 2026	**338,948**	**1,057,582**

INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

Basis of preparation

The summary financial statements of the Company have been prepared in accordance with all applicable International Financial Reporting Standards (IFRS). The financial statements have been prepared under the historical cost convention, as modified by available-for-sale financial assets, and financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRS) requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods.

These Financial Statements were approved and signed by:

....	....
Moukhtar Soalihu	**Eugenia Bulley**
(Managing Director)	**(General Manager, Finance and Administration)**